Modifi Biosciences, a leader in the development of direct DNA modification enabled cancer therapeutics, had announced that the company has been acquired by Merck, known as MSD outside of the United States and Canada. “In founding Modifi Biosciences, we sought to radically change...

Lundbeck has entered an agreement to acquire Longboard Pharmaceuticals for an equity value of $2.6 billion, aiming to strengthen its portfolio in the field of neuro-rare conditions. The transaction holds a net worth of $2.5 billion, assessed on a fully diluted basis. Lundbeck’s...

Agilent Technologies had announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted...

  Mankind Pharma has announced a definitive agreement for the acquisition of a 100% stake in Bharat Serums and Vaccines (BSV) from private equity investor Advent International in a Rs136.3bn ($1.6bn) deal. The move bolsters Mankind Pharma’s position in the Indian women’s...

Eli Lilly and Company has opened the Lilly Seaport Innovation Center (LSC), a research and development (R&D) hub in the Seaport district of Boston, US. The centre is set to progress the company’s work on RNA and DNA-based therapies and discover new drug targets for...

  Boehringer Ingelheim has acquired drug discovery and development company Nerio Therapeutics in a $1.3bn deal. Nerio’s small molecules inhibit the protein tyrosine phosphatases N1 and N2 (PTPN1 and PTPN2), which act as immune checkpoints. Through this mechanism, PTPN1/2...

Biogen has completed the acquisition of Human Immunology Biosciences (HI-Bio), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs). “We are very excited about the addition of felzartamab into our...

US-based biopharmaceutical company AbbVie has acquired Celsius Therapeutics, a biotechnology company developing therapies for inflammatory diseases, for $250m. The strategic move expands AbbVie’s footprint in the treatment of inflammatory diseases, adding a potentially transformative...

  Belharra Therapeutics has announced that it has entered a strategic partnership with global powerhouse Sanofi to spur the development of small molecule therapies for immunological diseases. Under the terms of the agreement, the San Diego, California-based next-generation...

  ANI Pharmaceuticals and Alimera Sciences had announced they have signed a definitive agreement pursuant to which ANI will acquire Alimera for $5.50 per share in cash at closing and one non-tradable contingent value right (CVR) representing the right to receive up to $0.50 per...